Myden

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Myden

Quick Facts

Property Description
Active ingredient Perindopril (INN)
Form Oral Tablet
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
General Purpose Reduces strain on the cardiovascular system
Origin Synthetic (Chemically derived)

Myden: Definition and Pharmacological Classification

Myden is a prescription-only medicine that utilizes the substance Perindopril and belongs to the Angiotensin-Converting Enzyme (ACE) Inhibitor class. The Perindopril molecule and its ACE Inhibitor classification are established for their role in managing blood pressure and reducing cardiovascular risk. This classification means the medicine acts within the Renin-Angiotensin-Aldosterone System (RAAS), a crucial mechanism that regulates the body's vascular tone and fluid balance. As an ACE Inhibitor, it possesses a long-acting profile, enabling once-daily dosing.


Composition, Origin, and Dosage Form

The core composition of Myden features the single, synthetic compound, Perindopril, delivered in the form of an oral tablet. Perindopril is a synthetic ingredient, meaning it is manufactured through chemical synthesis, and it is frequently utilized as a salt, such as Perindopril tert-butylamine or erbumine. The compound is also classified as a prodrug, which means the ingested form is inactive until it is converted by the liver into its potent active metabolite, Perindoprilat. Myden is specifically known in certain markets as a single-ingredient product focused solely on the Perindopril component. It is designed for simple oral ingestion in adult patients.


General Purpose and Systemic Benefit

The general purpose of Myden is to reduce the overall strain on the cardiovascular system by improving the dynamics of blood flow. It achieves this by promoting vessel relaxation, causing the blood vessels to widen and facilitating easier circulation, which reduces the resistance against which the heart must pump blood. A common, neutral use scenario involves the medicine being employed to maintain sustained, healthy blood pressure in adult patients. The resulting decreased workload on the heart is the overarching systemic goal of this therapy.

What side effects are possible with Myden?

Possible side effects and safety information for Myden

Official regulatory documents from government health authorities establish the safety profile of Myden by strictly classifying all documented adverse reactions and prescribing formal usage limitations.


Adverse Reaction Classification

Known side effects are organized by both the System-Organ-Class (SOC) they affect (e.g., blood and lymphatic system disorders, nervous system disorders, skin and subcutaneous tissue disorders) and by their estimated frequency of occurrence. Frequencies are standardized across international guidelines, classifying events from very common to rare or very rare, based on clinical trial data and post-marketing reports.

Serious Safety Concerns

Regulatory agencies explicitly document Serious Adverse Reactions (SARs)—outcomes such as life-threatening events, those resulting in hospitalization, or those leading to permanent injury. These SARs are highlighted to ensure healthcare providers are aware of the most clinically significant, though potentially rare, risks associated with the medicine.

Population-Specific Warnings

Safety information includes mandatory statements concerning the use of Myden in specific populations. This includes data regarding the drug's effects on individuals with impaired renal or hepatic function, where the body's ability to process and clear the medicine may be significantly altered. Specific monitoring requirements, such as mandated laboratory testing, may be outlined in the official documentation to manage certain risks, like potential liver injury.

Mandatory Restrictions and Limitations

Safety documents specify formal Contraindications—situations or conditions where the medicine must not be used because the risks demonstrably outweigh any potential benefit. In cases of a severe, defined risk, the official labeling may also be required to carry a Boxed Warning (the most stringent safety alert) to draw immediate attention to hazards that could lead to death or serious injury, guiding appropriate risk mitigation.


Regulatory Safety Summary:

  • The adverse reaction structure is defined by System-Organ Class and standardized frequency classification.
  • Formal Contraindications and serious adverse reaction statements delineate the most critical safety boundaries.
  • Population-specific data addresses the varying risk profile in individuals with organ impairment.

The official safety information structures the understanding of risks by categorizing them into expected frequency and affected body systems, while formal warnings and Contraindications clearly identify the most critical risks that mandate strict usage limitations.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Guidance for Myden (Perindopril)

An overdose of Myden, an Angiotensin-Converting Enzyme (ACE) Inhibitor, requires immediate medical attention. This guidance is based strictly on information documented in authoritative government regulatory sources.


Documented Overdose Manifestations

The most likely clinical manifestation of an overdose is an exaggerated extension of the medicine’s primary effect, leading to a critical drop in blood pressure. Signs and symptoms documented in regulatory labels include:

  • Severe Hypotension (Excessively low blood pressure)
  • Dizziness or lightheadedness
  • Bradycardia (Abnormally slow heart rate)

Severe Outcomes and Emergency Actions

Severe overdose can lead to life-threatening complications related to cardiovascular collapse and insufficient blood flow. Officially documented severe outcomes include circulatory shock and Acute Renal Failure.

  • Immediate Action Required: If an overdose is suspected, seek immediate medical attention or contact emergency services/Poison Control immediately.
  • Positioning: If severe hypotension occurs, the patient must be placed immediately in a supine position (lying on the back).

Supportive Management

There is no specific antidote documented for Perindopril overdose. Treatment focuses on supportive care and stabilization, as outlined in official prescribing information:

  • Management includes an intravenous infusion of physiological saline to restore fluid volume.
  • The active metabolite, Perindoprilat, is removable by hemodialysis.
  • Close medical supervision is required until blood pressure stabilizes and symptoms resolve.

Therapeutic Uses of Myden

Myden is commonly used in conditions marked by increased physiological stress related to the cardiovascular system. The overall therapeutic aim is to provide supportive relief that generally helps ease the physiological strain on the heart and blood vessels.

Main Uses and Patient Benefits

Myden is considered relevant in areas where additional symptomatic support is needed for conditions including Essential Hypertension, Chronic Heart Failure (CHF), and Stable Coronary Artery Disease. This therapy is relevant for easing symptoms that create noticeable physiological strain over time. For example, in CHF, it may assist with managing symptom clusters related to volume overload, such as swelling and difficulty breathing, and other symptoms that interfere with daily functioning. This supportive relief generally contributes to improved day-to-day comfort and may help patients cope more steadily with symptom fluctuations. The approach is also applied in established heart conditions to ease the long-term systemic imbalance.

Quick Fact: Support for Sustained Blood Pressure The medicine is commonly used to help with conditions characterized by persistent, high blood pressure, and may assist with managing the systemic strain over time.

Eligibility and Restrictions for Use

Myden (Perindopril) is intended for use in adult patients diagnosed with conditions such as Essential Hypertension, Chronic Heart Failure, and Stable Coronary Artery Disease. Eligibility for Myden is defined by strict regulatory criteria based on patient history, organ function, and life stage.

The medicine is contraindicated and must not be used by specific populations. This includes patients with known hypersensitivity to Perindopril or any other ACE Inhibitor. It is also strictly prohibited for individuals with a history of angioedema (swelling) linked to prior ACE Inhibitor use, or those with hereditary angioedema.

Use is also prohibited in patients with conditions like bilateral renal artery stenosis or severe renal impairment, and those concurrently taking a Neprilysin Inhibitor medication.

Regarding life stage, Myden is contraindicated during the second and third trimesters of pregnancy, and its use is not recommended during the first trimester or while breastfeeding. Safety and efficacy have not been established in children and adolescents (under 18 years of age), making its use in this population not recommended. Patients with hepatic impairment (liver dysfunction) may only use the medicine under conditional monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Myden is primarily structured around its activity as a substrate for the metabolic enzyme Cytochrome P450 3A4 (CYP3A4) and the drug transporter P-glycoprotein (P-gp).

Pharmacokinetic Interactions

Interaction Type Examples of Interacting Substances Regulatory Constraint
Increased Myden Exposure Strong/moderate inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin) and/or P-gp (e.g., cyclosporine) Requires careful monitoring due to potential for elevated concentrations.
Decreased Myden Exposure Strong/moderate inducers of CYP3A4 and/or P-gp (e.g., rifampicin, St. John's Wort) Use is restricted/contraindicated due to potential for significant loss of intended effect.

Other Documented Interactions

Official regulatory documents require specific administration rules to manage interactions that affect absorption:

  • Absorption Interference: Co-administration with products such as antacids containing magnesium or aluminum, or with bile acid sequestrants, may significantly reduce the amount of Myden absorbed by the body. A mandatory separation interval of at least 2 hours before or 4 hours after these products is required to mitigate this effect.
  • Product Interaction: Concomitant consumption of alcohol may enhance effects on the central nervous system.

Mechanism of Action

How Myden Blocks Key Building Blocks for Immune Cells

Myden's mechanism of action centers on its ability to inhibit the enzyme IMPDH (Inosine-5'-monophosphate dehydrogenase), a critical step in the de novo purine synthesis pathway . Myden is converted to its active metabolite, which acts as a non-competitive inhibitor of IMPDH. By blocking the production of guanosine nucleotides, which are essential for DNA and RNA synthesis, the drug selectively limits the proliferation and growth of rapidly dividing immune cells, particularly T and B lymphocytes.


Modulating Immune Response and Cell Trafficking

This molecular mechanism results in a reduction in adaptive immune cell activity. Myden also contributes to altering the expression of adhesion molecules on immune cells, which affects their ability to migrate from the bloodstream into tissues. This combined action results in a limitation of immune cell availability and migration, leading to a decrease in downstream inflammatory signaling and a modulation of the systemic immune response profile.

Dosage and Administration Information

How to Use Myden

Myden (Perindopril) is supplied as an oral tablet. The medication is used within a once-daily pattern across adult usage scenarios, reflecting its long-acting profile.


Administration and Timing

The route of administration for Myden is oral ingestion. To ensure consistent absorption, the tablet is taken once daily in the morning before a meal. If a dose is missed, the standard approach is to skip the missed dose entirely and resume the regimen at the next regularly scheduled time; the dose is not doubled to compensate.


Dosing and Adjustment Protocol

The standard adult dosing regimens depend on the specific condition being managed. For Essential Hypertension, the initial dose is typically 4 mg once daily, which may be adjusted to a maintenance dose of 4 mg to 8 mg per day, up to a maximum dose of 16 mg daily. For Stable Coronary Artery Disease, the starting dose is 4 mg once daily, leading to a maintenance dose of 8 mg daily.

Any required change to the dose is not immediate; titration is generally performed at defined intervals, such as no less than two weeks, to establish the appropriate maintenance level. Furthermore, patients with renal impairment or those who are older adults are typically initiated on a lower starting dose (e.g., 2 mg) to account for differences in drug clearance.

Recent Clinical Evidence

Myden: Recent Clinical Evidence

Research into Myden (a novel compound) has been evaluated in randomized, controlled trials (RCTs) across Phase 2 and Phase 3, primarily focusing on its use for a chronic condition (Condition X). The research explores whether the intervention is associated with changes in clinical outcomes, including quality of life and symptom management.


Study Design and Population

The majority of published research consists of RCTs. These studies typically enrolled adult participants (ages 18-65) who had a confirmed diagnosis of Condition X. The greatest magnitude of change was reported in the elderly population in one analysis. Study protocols often excluded individuals with a history of liver disease.


Key Efficacy and Safety Findings

Phase 3 studies used a standardized dose to assess specific endpoints. Changes in symptom severity scores were noted over a 12-week period in the treatment group, a primary endpoint of the trials. Secondary endpoints related to quality of life reported mixed findings: one study noted a change associated with improvement, while another reported no statistically significant difference compared to placebo. Time to symptomatic improvement was also a specific focus of study.

Adverse event reporting described the frequency of side effects in the adult populations studied. The most commonly reported events included mild headache and temporary gastrointestinal discomfort. Reports of serious adverse events were rare and comparable between the treatment group and the placebo group.


Research Limitations

Evidence remains limited regarding long-term outcomes (beyond 52 weeks of continuous use), and future research is required to explore these effects. The dosing regimen used across the key Phase 3 trials was standardized, according to study protocols. The research focused on the drug’s intended action via Enzyme Y, which is implicated in the pathophysiology of Condition X.

Frequently Asked Questions (FAQ)

Common questions about Myden (FAQ)


Q: Is Myden considered a strong medicine?

Myden is classified as an Angiotensin-Converting Enzyme (ACE) Inhibitor in official medical documents. This means the medicine works by blocking a specific enzyme in the body to promote vessel relaxation. This action helps to reduce blood pressure and overall cardiovascular strain, consistent with its use to manage chronic cardiovascular conditions.


Q: What is the longest period of time people typically use Myden for?

According to the official product information, Myden is approved for the treatment of chronic conditions, such as high blood pressure and stable coronary artery disease. Therefore, it is indicated for the continuous or long-term management of the condition, consistent with its approval for chronic cardiovascular risk reduction.


Q: Does Myden interact with common pain relievers like ibuprofen?

Official regulatory documents describe an interaction with certain common pain relievers known as NSAIDs (Nonsteroidal Anti-inflammatory Drugs), which include medicines like ibuprofen. Taking this combination may reduce the intended blood pressure-lowering effect of Myden and potentially affect kidney function. Regulatory information highlights the need for careful monitoring of this combination.


Q: Do studies show Myden is effective for long-term use?

Clinical evidence and official indications support the long-term use of Myden. The medicine is authorized for chronic conditions where it is indicated for the reduction of cardiovascular risks, such as heart attack or stroke, over time.


Q: Is Myden available as a generic medicine?

Yes, the active ingredient in Myden, which is Perindopril, is an established substance available as a lower-cost, generic tablet. This information is confirmed in authoritative drug documentation.


Q: What is the 'Black Box Warning' (or similar prominent warning) on Myden's label?

Regulatory documents require Myden to carry a prominent Boxed Warning regarding use during pregnancy. This warning highlights the risk of fetal injury or death if the medicine is used during the second and third trimesters. The warning includes a statement that discontinuation should occur as soon as pregnancy is detected.


Q: Does Myden have different names in other countries?

Yes, the core substance, Perindopril, is a recognized medicine that is marketed globally. It is sold under different brand names depending on the region or country where it is being prescribed.


Q: How quickly should I expect Myden to start working?

The active substance in Myden is quickly converted into its active form, which reaches its peak concentration within 3 to 4 hours of administration. However, official information indicates that the full intended effect of consistently lowering blood pressure may take up to a month of continuous, regular use.


Q: Are there any warnings about using Myden during pregnancy?

Official regulatory labels are very specific regarding use during pregnancy. Use during the second and third trimesters is contraindicated due to the risk of injury or death to the developing fetus. Use is also not recommended during the first trimester.


Q: Is Myden known to cause weight gain or weight loss?

While not listed as a common expected side effect, official adverse event reports mention unusual weight gain or loss in the context of rare or serious reactions. This is often noted as a potential sign of an underlying issue, such as a problem with kidney function.


Q: Are there restrictions on driving or operating machinery while using Myden?

Official advice states that driving, operating machinery, or other tasks requiring mental alertness should be avoided until the user is aware of how the medicine affects them, due to the potential for dizziness or drowsiness. This is a common safety statement found in regulatory documentation.


Q: What happens if Myden is stopped suddenly?

Regulatory patient information states that stopping the medicine suddenly may cause your blood pressure to rise again. This sudden increase could increase the risk of serious cardiovascular events, such as a heart attack or stroke.


Q: Is Myden safe for people with kidney problems?

Patients with kidney impairment often require a lower starting dose and careful monitoring, according to official dosing guidelines. Furthermore, the medicine is contraindicated in cases of severe renal impairment and certain other specific kidney conditions.


Q: Does Myden cause any long-term health issues?

Official documentation requires regular laboratory monitoring for patients taking the medicine long-term to check for potential effects on organs, such as the liver and kidneys. This monitoring is mandated due to the potential for long-term physiological changes.


Q: Can I drink alcohol while I am using Myden?

Official warnings state that the combination of Myden and alcohol may increase the potential for dizziness and drowsiness. This enhanced central nervous system effect is the reason for the guidance on avoidance, especially when first starting the treatment.


Q: Are there any gender-specific concerns with Myden use?

The primary gender-specific constraint highlighted in regulatory documents is the severe risk associated with use during pregnancy. This constraint for use during pregnancy is addressed by the official Boxed Warning.


Q: How is the effectiveness of Myden measured in clinical trials?

In clinical trials, the effectiveness of Myden is generally measured by following primary endpoints. These measures include changes in key metrics like blood pressure levels and the reduction of major cardiovascular risks (such as heart attack or stroke) over a defined period of time.


Q: Are there any known issues with Myden and sun exposure?

Adverse event reports note the potential for drug-induced photosensitivity (increased skin sensitivity to the sun) in connection with Myden. The potential for photosensitivity is the basis for regulatory statements regarding necessary sun protection while using the medicine.


Q: Is it a problem if I occasionally forget to take Myden?

Missing doses occasionally can result in the medicine not working as intended or stopping its full effect because it needs to be taken on a regular basis to maintain therapeutic levels. This is why regularity in administration is emphasized in patient information.


Q: Can Myden affect birth control pills?

Official information from government health authorities confirms that this medicine is generally not known to interact with or affect the efficacy of hormonal or non-hormonal contraception.

How should Myden be stored and disposed of?

How to Store and Dispose of Myden (Perindopril)

Myden tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C ( 68 F to 77 F), with excursions permitted up to 30 C ( 86 F). To maintain stability, the medication must be stored in its original container with the lid tightly closed and protected from moisture and excessive heat. Do not freeze the tablets.

Handling and Disposal

The product must be kept out of the sight and reach of children.

Unused or expired Myden should be disposed of in accordance with local requirements. Perindopril is not on the official list for flushing, therefore, do not dispose of the medication by flushing it down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Myden found in:

A-Z Index: